Adverse Effects Of Anemia Research Articles

Combination of Beetroot Juice, Honey and Green Apple on Hemoglobin Levels in Anemia Pregnant Women at Payung Sekaki Health Center, Pekanbaru

Anemia is a medical condition characterized by lower-than-normal hemoglobin (Hb) levels. In pregnant women, anemia can lead to prolonged delivery times, increased bleeding, and shock during contractions. The adverse effects of anemia on the fetus include premature birth, low birth weight (LBW), potential disabilities, and infant mortality. The recommended solution to overcoming anemia in pregnant women is to consume a combination of beetroot juice and green apples juice. Beets contain essential components that can elevate Hb levels, whereas green apples provide minerals and vitamin C, enhancing iron absorption (Fe). This study aimed to investigate the effect of a combination of beetroot juice and green apple juice on Hb levels in pregnant women with anemia. The study population was comprised of 200 normal pregnant women, with a sample size of 15 in trimester III (TM III) with anemia, selected through purposive sampling. The intervention involved administering the juice daily for seven days. Data were collected using observation sheets and easy-to-touch devices. The research design was pre-experimental, utilizing a one-group pre-test–post-test design. This study was conducted within the working area of the Payung Sekaki Public Health Center (PHC) from January to April 2022. Dependent T-test analysis was used for data evaluation. The average Hb level of TM III pregnant women before juice consumption was 9.7 g/dL, which increased to 10.6 g/dL after the intervention. The dependent t-test results, with a 95% confidence level (Cl), indicated a p-value of 0.000, signifying a significant impact of fruit juice on the Hb levels of TM III pregnant women experiencing anemia. These findings suggest that clinical midwives should educate pregnant women about the importance of Fe tablets and the positive influence of fruit juice on Hb levels.

THE EFFECT OF HEALTH PROMOTION USING EMO DEMO VIDEO ON THE SELECTION OF FOOD CONTAINS IRON FOR ANEMIA PREVENTION IN ADOLESCENTS: STUDY AT ISLAMIC SENIOR HIGH SCHOOL IN YOGYAKARTA

Background. Emotional Demonstration (Emo Demo) is a technique to educate the public through the latest approach from the theory of Behavior Center Design as a reference. This strategy can be an alternative to help young women in choosing food ingredients to prevent anemia. Given the adverse effects of anemia, it is necessary to overcome them. Objective. This study aims to assess the effect of health promotion through Emo Demo video media on selecting foods containing iron to prevent anemia in adolescent girls. Method. The research design was a pre-post test with a control group design and quasi-experimental design. The research design used in this research is "Control Group Design". In this study, there were two groups, namely the intervention group using the Emo Demo video method and the control group using e-leaflets. Results. Emo Demo video promotion has a positive effect on knowledge (p value 0.000), attitudes (p value 0.000), and behavior (p value 0.000) in adolescent girls to prevent anemia compared to e-leaflets. Conclusion. Emo Demo video as a learning media is more effective in increasing knowledge, attitudes, and behavior in choosing foods high in iron in adolescent girls than in the group using e-leaflets. It is important to provide continuous Emo Demo videos and do the monitoring of adolescent girls to prevent anemia.

The effect of mother’s β-thalassemia minor on placental histology and neonatal outcomes

Objective β-thalassemia is a prevalent disease in Iran. The adverse effects of anemia on placental and neonatal outcomes have previously been shown. Women require additional iron during pregnancy and the anemia of women with β-thalassemia may adversely affect the neonatal outcome and increase placental abnormalities. In this study, we compared the placental histology and neonatal outcomes among pregnant women with and without β-thalassemia. Material and methods In this population-based cross-sectional study, 144 pregnant women with β-thalassemia minor (case group) were compared to 142 women without β-thalassemia (control group). Women with singleton pregnancies over 20 weeks of gestation without pregnancy complications, anemia, collagen vascular diseases, or other hemoglobinopathies, all referred to hospitals affiliated to Shiraz University of Medical Sciences from March 2014 to February 2016, were included and maternal and neonatal data were extracted from medical records. After child birth, the placenta was evaluated for macroscopic and microscopic changes. Results The frequency of LBW was significantly higher in the case group than that in the control group (19.7 vs. 9.7%, respectively) (p = .019). Six in the case group had gross abnormalities of placenta, while none in the control group (p = .03) and the case group had a higher frequency of chorangiosis, calcification, syncytial knot, and umbilical cord position (p < .05). Conclusion As β-thalassemia increases the chance of placental abnormalities, it is recommended to pay more attention to patients with β-thalassemia, especially during pregnancy, to prevent placental and neonatal adverse outcomes.

ANEMIA;

Background: Moderate to severe anemia during pregnancy is associated withincreased maternal and fetal morbidity and mortality. Therefore moderate to severe maternalanemia is a high risk group and it is imperative that all cases of anemia should be identified andtreated to ensure adequate hemoglobin level before labour. Different countries have shownconsiderable variations in the prevalence of moderate to severe anemia during pregnancy.Objective: To determine the frequency of moderate to severe anemia during pregnancy and itsassociation with socio-demographic and obstetric characteristics. Study Design: Crosssectionaldescriptive study. Place and duration of Study: This study was conducted from 1stOctober 2011 to 31st March 2012, in the obstetrics and gynaecology department of Sir SyedHospital, a tertiary care hospital in Karachi. Methodology: The patients attending the antenatalOPD between the gestational age of 20 to 41weeks who were moderate to severely anemic (according to WHO criteria based on Hb level) were selected for the study. A self-designedproforma was then utilized to obtain relevant information. This proforma covered sociodemographicas well as patient’s obstetric characteristics. Result: The frequency of anemia wasfound to be 42% (633/1507).Patients with moderate to severe anemia after 20 weeks till 41 weekswere 323. Patients with moderate anemia were 268/323 (83%), while 55/323 (17%) women hadsevere anemia. Majority of women with moderate anemia were multiparous between 26-32 yearsof age and presented between 35-41 weeks gestation. Majority of women with severe anemiawere primigravidas between 18-25 years and presented in late third trimester. Conclusions: Ourstudy revealed multiparity, illiteracy, poverty and late antenatal booking as the factors responsiblefor the severity of anemia during pregnancy. Therefore, anemia should be recognized as aserious public health problem. The adverse effects of anemia can be avoided by counseling onbirth spacing and early antenatal booking.

Targeting Anemia in Patients with Lung Cancer

Anemia is highly prevalent in patients with lung cancer, often occurring at baseline and frequently exacerbated as a result of treatment with platinum-based chemotherapy. Anemia has been shown to have a negative effect on quality of life in patients with lung cancer, and additional data indicate that decreases in hemoglobin in these patients are associated with impaired survival. Multiple clinical studies have demonstrated that treatment of anemia with erythropoietic agents in patients with lung cancer results in a significant increase in hemoglobin, decrease in transfusions, and improvement in quality of life. Ongoing research is evaluating whether erythropoietic therapy can reduce cognitive impairment associated with lung cancer, cytotoxic therapy, and anemia. Despite the known adverse effects of anemia and the established benefits of erythropoietic therapy in anemic patients with lung cancer, more than half of these patients do not receive any anemia treatment. The purpose of this review is to report results of the European Cancer Anaemia Survey that describe the prevalence of anemia in patients with lung cancer, to review the major studies evaluating the clinical outcomes of erythropoietic therapy in patients with lung cancer, to discuss the recent safety concerns regarding the use of erythropoietic agents in patients with cancer treated to high hemoglobin levels, and to describe various novel therapeutic applications of erythropoietic agents in lung cancer.

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree of neurologic recovery. A randomized, double-blind, controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease. Patients either received 500 mg of trientine hydrochloride 2 times per day or 20 mg of tetrathiomolybdate 3 times per day with meals and 20 mg 3 times per day between meals for 8 weeks. All patients received 50 mg of zinc 2 times per day. Patients were hospitalized for 8 weeks, with neurologic and speech function assessed weekly; discharged taking 50 mg of zinc 3 times per day, and returned annually for follow-up. A university hospital referral setting. Primarily newly diagnosed patients with Wilson disease presenting with neurologic symptoms who had not been treated longer than 4 weeks with an anticopper drug. Treatment with either trientine plus zinc or tetrathiomolybdate plus zinc. Neurologic function was assessed by semiquantitative neurologic and speech examinations. Drug adverse events were evaluated by blood cell counts and biochemical measures. Six of 23 patients in the trientine arm and 1 of 25 patients in the tetrathiomolybdate arm underwent neurologic deterioration (P<.05). Three patients receiving tetrathiomolybdate had adverse effects of anemia and/or leukopenia, and 4 had further transaminase elevations. One patient receiving trientine had an adverse effect of anemia. Four patients receiving trientine died during follow-up, 3 having shown initial neurologic deterioration. Neurologic and speech recovery during a 3-year follow-up period were quite good. Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease.

Mild anemia is associated with greater symptom burden (SB) and reduced quality of life (QoL) in cancer patients

8123 Background: Standard treatment guidelines for AC are not implemented until Hgb concentration falls below 10 g/dL. However, adverse effects of anemia may occurr at higher Hb thresholds. The obj...